Wall Street analysts expect that IDEAYA Biosciences, Inc. (NASDAQ:IDYA) will announce earnings per share (EPS) of ($0.07) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for IDEAYA Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at $0.98. IDEAYA Biosciences posted earnings per share of ($0.59) during the same quarter last year, which would indicate a positive year-over-year growth rate of 88.1%. The business is scheduled to report its next quarterly earnings report on Wednesday, August 11th.
On average, analysts expect that IDEAYA Biosciences will report full-year earnings of ($0.97) per share for the current year, with EPS estimates ranging from ($2.00) to ($0.29). For the next financial year, analysts forecast that the company will post earnings of ($1.55) per share, with EPS estimates ranging from ($3.03) to ($0.60). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow IDEAYA Biosciences.
IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Sunday, May 9th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The firm had revenue of $7.25 million during the quarter, compared to the consensus estimate of $9.97 million.
In other news, SVP Michael P. Dillon sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, June 7th. The shares were sold at an average price of $20.22, for a total transaction of $30,330.00. Following the sale, the senior vice president now owns 100,289 shares of the company’s stock, valued at approximately $2,027,843.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael P. Dillon sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 11th. The stock was sold at an average price of $20.22, for a total transaction of $101,100.00. Following the sale, the senior vice president now directly owns 103,789 shares in the company, valued at approximately $2,098,613.58. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its stake in shares of IDEAYA Biosciences by 59.2% during the 1st quarter. Royal Bank of Canada now owns 1,694 shares of the company’s stock worth $40,000 after purchasing an additional 630 shares during the period. Panagora Asset Management Inc. grew its stake in IDEAYA Biosciences by 167.1% in the 1st quarter. Panagora Asset Management Inc. now owns 1,731 shares of the company’s stock valued at $41,000 after acquiring an additional 1,083 shares during the period. Clearstead Advisors LLC acquired a new stake in IDEAYA Biosciences in the 1st quarter valued at $44,000. Lazard Asset Management LLC acquired a new stake in IDEAYA Biosciences in the 1st quarter valued at $44,000. Finally, Dorsey Wright & Associates grew its stake in IDEAYA Biosciences by 134.9% in the 1st quarter. Dorsey Wright & Associates now owns 1,980 shares of the company’s stock valued at $47,000 after acquiring an additional 1,137 shares during the period. 69.90% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:IDYA opened at $21.66 on Tuesday. IDEAYA Biosciences has a fifty-two week low of $7.20 and a fifty-two week high of $24.92. The company has a market cap of $712.74 million, a PE ratio of -17.75 and a beta of 1.92. The firm has a 50-day moving average price of $20.19.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.